Cosunter(SZ:300436) 智通财经网·2025-10-10 11:57Core Insights - Guangshengtang's innovative drug GST-HG131 has received significant recognition from the American Association for the Study of Liver Diseases (AASLD), with its Phase II clinical trial results accepted for presentation at The Liver Meeting® 2025 [1][2] Group 1: Clinical Trial Results - GST-HG131 is the world's first oral HBsAg inhibitor to complete Phase II clinical trials, demonstrating good accessibility and patient compliance [2] - In the Phase II trial, HBsAg levels decreased rapidly, with the fastest patient showing a reduction of approximately 0.8 Log10 IU/mL within 7 days; the third group (30mg, BID, three-month treatment) achieved an average reduction to 12.88%, representing an 87.12% decrease [2] - 76.5% of patients in the third group reached HBsAg levels ≤100 IU/mL, a key indicator of partial cure, with sustained reductions observed even after treatment cessation [2] Group 2: Mechanism and Future Prospects - GST-HG131 exhibits significant suppression of HBsAg, while GST-HG141 further inhibits HBV DNA and has potential effects on HBV cccDNA, preventing viral rebound [3] - The combination of GST-HG131 and GST-HG141 in a Phase II clinical trial for previously treated hepatitis B patients is expected to challenge clinical cure outcomes, supported by national policies for innovative drug development [3]